Dai Hashimoto
Overview
Explore the profile of Dai Hashimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mochizuka Y, Enomoto N, Daisuke A, Inoue Y, Yasui H, Hozumi H, et al.
Am J Respir Crit Care Med
. 2023 Oct;
209(1):e1-e3.
PMID: 37788379
No abstract available.
12.
Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y, et al.
J Immunother Cancer
. 2023 Jul;
11(7).
PMID: 37500182
Background: There has been no prospective trial for treatment of immune-related pneumonitis (irP) occurred after immune checkpoint inhibitors (ICIs). Methods: In this single-arm phase II study, patients with cancer with...
13.
Tanaka Y, Suzuki Y, Saku A, Kono M, Hashimoto D, Hasegawa H, et al.
Rheumatology (Oxford)
. 2023 Jul;
63(4):1162-1171.
PMID: 37458486
Objectives: Fibrotic interstitial lung disease (ILD) is a progressive lung disease characterized by loss of lung volume, resulting in a leading cause of death in patients with RA. Crucially, acute...
14.
Assessment of malnutrition-related risk in patients with idiopathic pleuroparenchymal fibroelastosis
Suzuki Y, Fukada A, Mori K, Kono M, Hasegawa H, Hashimoto D, et al.
ERJ Open Res
. 2023 May;
9(3).
PMID: 37228291
Background: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is characterised by upper lobe-dominant fibrosis involving the pleura and subpleural lung parenchyma, with advanced cases often complicated by progressive weight loss. Therefore, we hypothesised...
15.
Kono M, Oshima Y, Katsumata M, Hirama R, Takeda K, Mochizuka Y, et al.
Intern Med
. 2023 May;
63(1):119-124.
PMID: 37225487
A 48-year-old woman was admitted to our hospital with acute respiratory failure. Chest computed tomography showed ground-glass opacity and patchy emphysematous lesions in both lungs. Corticosteroid therapy was effective; however,...
16.
Mochizuka Y, Suzuki Y, Kono M, Hasegawa H, Hashimoto D, Yokomura K, et al.
Respirology
. 2023 May;
28(8):775-783.
PMID: 37221050
Background And Objective: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive lung fibrosis of unknown aetiology. Epidemiological studies have suggested that IPF progression may negatively affect nutritional status. Weight loss...
17.
Inoue Y, Inui N, Karayama M, Asada K, Fujii M, Matsuura S, et al.
Cancer Immunol Immunother
. 2023 Apr;
72(8):2717-2728.
PMID: 37099186
Whether circulating levels of specific cytokines at baseline link with treatment efficacy of immune checkpoint blockade (ICB) therapy in patients with non-small cell lung cancer remains unknown. In this study,...
18.
Takeda K, Miwa H, Kono M, Hirama R, Oshima Y, Mochizuka Y, et al.
Respir Med Case Rep
. 2023 Mar;
42:101824.
PMID: 36910019
A 75-year-old woman was admitted to our hospital with progressive dyspnea 7 months after second-line treatment with pembrolizumab for advanced non-small cell lung cancer. Chest radiography revealed hyperinflation in both...
19.
Karayama M, Aoshima Y, Suzuki T, Mori K, Yoshizawa N, Ichikawa S, et al.
Eur Respir J
. 2023 Feb;
61(5).
PMID: 36822633
Background: Acute exacerbation of idiopathic interstitial pneumonias (AE-IIPs) induces permanent pulmonary dysfunction and is potentially lethal. The unpredictable occurrence of AE-IIPs remains an important clinical issue in the management of...
20.
Kono M, Tsunoda T, Ikeda S, Yagi S, Hirama R, Watanuki M, et al.
Respir Investig
. 2023 Feb;
61(2):210-219.
PMID: 36773509
Background: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is heterogeneous, with some patients showing a progressive decline in forced vital capacity (FVC). However, the clinical features of these cases with progressive phenotypes remain...